Approach & Track Record
Partnership built on the spirit of collaboration
At Forest, we seek collaborative opportunities in all phases of development—from
products in pre-clinical development to those ready for FDA review—as well as co-promotional
arrangements for approved products.
To take advantage of the benefits of each potential therapy, our approach follows
the basic principles of a successful partnership—the ability to quickly apply expertise,
maintain a high level of product focus, and remain agile at every stage of development.
These basic principles allow us to be open to virtually any therapeutic category,
including the areas in which we are currently active:
- CNS
- Respiratory
- Inflammation
- Metabolic
- Cardiovascular
- Pain
- Gastroenterology
- Infectious disease
Our track record
There are many examples that highlight how a collaborative approach in developing
and marketing in-licensed products has solidified and deepened our partnerships.
Forest’s long-term alliance with H. Lundbeck A/S began when the company in-licensed
the antidepressant Celexa® (citalopram HBr) for marketing in the United States
and then was extended to include the antidepressant
Lexapro® (escitalopram oxalate). Forest successfully brought both Celexa
and Lexapro to market, eventually creating the fastest-growing antidepressant franchise
in the United States.
Forest’s agreement with Daiichi Sankyo Pharma Inc. to co-promote Benicar®
(olmesartan medoxomil) and Benicar HCT® (olmesartan medoxomil-hydrochlorothiazide) was signed after the submission of the NDA, ensuring
the important new antihypertensive agent would be supported by Forest’s sales and
marketing strength.
Other successful partnerships include:
Forest’s Products
Learn more about Forest’s marketed products
